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Background and objectives: Mutations in nephrin (NPHS1) and podocin (NPHS2) genes represent a major cause of
idiopathic nephrotic syndrome (NS) in children. It is not yet clear whether the presence of a single mutation acts as a modifier
of the clinical course of NS.
Design, setting, participants, & measurements: We reviewed the clinical features of 40 patients with NS associated with
heterozygous mutations or variants inNPHS1 (n 7) orNPHS2 (n 33). Long-term renal survival probabilities were compared
with those of a concurrent cohort with idiopathic NS.
Results: Patients with a single mutation inNPHS1 received a diagnosis before those with potentially nongenetic NS and had
a good response to therapies. Renal function was normal in all cases. For NPHS2, six patients had single heterozygous
mutations, six had a p.P20L variant, and 21 had a p.R229Q variant. Age at diagnosis and the response to drugs were comparable
in all NS subgroups. Overall, they had similar renal survival probabilities as non-NPHS1/NPHS2 cases (log-rank 2 0.84, P 
0.656) that decreased in presence of resistance to therapy (P < 0.001) and in cases with renal lesions of glomerulosclerosis and
IgM deposition (P < 0.001). Cox regression confirmed that the only significant predictor of dialysis was resistance to therapy.
Conclusions: Our data indicate that single mutation or variant in NPHS1 and NPHS2 does not modify the outcome of
primary NS. These patients should be treated following consolidated schemes and have good chances for a good long-term
outcome.
Clin J Am Soc Nephrol 4: 1065–1072, 2009. doi: 10.2215/CJN.03910808
T he discovery of podocyte genes that cause familial ne-phrotic syndrome (NS) allows a more appropriate ap-proach to patients with NS, especially in children with
a familial history of proteinuria (1,2). There is growing evidence
that mutations in genes coding for slit diaphragm proteins
frequently also occur in sporadic NS and are associated with
potentially variable clinical outcome (3–9). Most reports have
focused on monogenic diseases involving two major genes—
nephrin (NPHS1) and podocin (NPHS2)—that together cause
almost 60% of the cases of NS in those who are younger than 1
yr and in adolescents (10). A still unresolved issue is the clinical
impact of heterozygous mutations and/or variants of NPHS1/
NPHS2 because the contribution of heterozygous alleles to NS
has received heterogeneous interpretation (3,9,11–16). In par-
ticular, it is unknown whether patients who carry a single
mutation represent a separate clinical entity, because no data
on response to drugs and on the long-term clinical outcome are
available.
The reason for an association of NPHS1 and NPHS2 het-
erozygous mutations with NS remains elusive, because these
are recessive conditions that require a molecular defect on both
alleles to determine a pathologic effect. One explanation may be
a digenic inheritance whereby a mutation of another gene
affects the slit diaphragm assembly. Moreover, the presence of
a heterozygous mutation or variant in NPHS1 or NPHS2 may
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act as a modifier of the phenotype and represent a clinical
problem in terms of prognosis, drug response, and long-term
outcome. Data on this aspect are scattered and offer no practical
opportunity for discussion (3,9,11–16).
This article reports the clinical features of 40 patients with NS
associated with heterozygous mutations/variants of NPHS1 or
NPHS2. Renal survival probabilities of these children were
compared with those of a concurrent cohort of children with
classical idiopathic NS.
Materials and Methods
Patients
Forty patients who had sporadic NS with single mutations or func-
tional variants in the NPHS1 (n  7) or NPHS2 (n  33) gene were
retrospectively analyzed with respect to their major clinical features.
They belong to a population of patients who were referred for NS to a
second-level nephrology unit in Italy and underwent a detailed molec-
ular screening to exclude genetic diseases that potentially are unre-
sponsive to drugs. Relevant clinical features were compared with data
from 28 patients with NS for homozygous or compound heterozygous
mutations of NPHS1 (n  11) and NPHS2 (n  17) genes, respectively,
and 221 children with idiopathic NS. Prerequisite for enrollment was
the presence of nephrotic proteinuria (40 mg/kg per d), absence of
episodes of hematuria, and negativity of tests for autoimmunity (anti-
bodies against native DNA, p/cANCA). Following our diagnostic flow-
chart, patients who presented with NS before 1 yr of age and/or those
who were older than 16 yr had a renal biopsy. Between 1 and 16 yr,
only those with resistance to steroids or to combined therapy with
steroids and cyclosporin A (CsA) underwent the biopsy procedure.
Patients who showed secondary and primary renal diseases other than
congenital nephrosis of the Finnish type (17), diffuse mesangial sclero-
sis, minimal changes, mesangial proliferation with IgM deposition, or
FSGS were excluded (18). As a rule, the therapeutic approach started
with steroids 60 mg/m2 per d for 30 to 60 d (19,20), and in case of
unresponsiveness (partial or global), three pulses of methylpred-
nisolone were given (10 mg/kg) at successive days followed by another
three with reduced dosages (5 mg/d) every other day. Steroids were
then associated with CsA (5 mg/kg starting dosage, followed by taper-
ing to reach the minimum dosage required to maintain CsA serum
trough levels between 50 and 100 ng/ml). Steroid resistance was con-
sidered the failure to achieve remission of proteinuria after completion
of the oral and pulse treatment. CsA resistance was the failure to
modify proteinuria after 24 wk of CsA; intolerance was considered the
worsening of renal function (creatinine clearance 70% of pre-CsA
values) and/or the increment of mean arterial BP (50%) after the start
of therapy. In case of CsA resistance, a few patients received tacrolimus
(starting dosage 0.1 mg/kg followed by modification to maintain a
trough level between 5 and 10 ng/ml).
The basic molecular approach included sequencing of NPHS1,
NPHS2, and exons 8 and 9 of WT1. Adult patients and parents (for
patients who were younger than 18 yr) were requested to give the
informed consent for DNA analysis and for reviewing their clinical
parameters. Patients who were enrolled in the study were numbered,
and data were evaluated anonymously (access key numbers were in
possession of the senior author [G.M.G.] only).
Mutation Analysis
Genomic DNA was extracted according to standard procedures.
Molecular analyses of NPHS1, NPHS2, and WT1 were performed by
direct sequencing as described previously (2,21–24). Primer sequences
were selected on the basis of literature reports by different groups.
Exons were amplified by PCR using flanking intronic primers and
subjected to heteroduplex analysis (DHPLC) and/or automatic se-
quence analysis by dye-terminator reaction (automated sequencer ABI
3100; Applera, Milan, Italy).
Statistical Analysis
NPHS1 and NPHS2 were analyzed separately. Podocin data were
compared with those from children with non-NPHS1/NPHS2 NS. Data
are expressed as mean  SD, median and interquartile range, or fre-
quencies. Bivariate relationships were analyzed by t test or rank-sum
test, and 2 or Fisher exact test as appropriate. Renal survival times
from disease onset to dialysis initiation were described using the
Kaplan-Meier method. Cox regression was used to model the risk for
dialysis as a function of the diagnosis considering age at disease onset,
gender, clinical characteristics, and histologic patterns as covariates.
Model specification, proportionality assumption, and overall fit were
checked by reestimation and formal and graphical tests on the basis of
residuals and testing of the interaction with time of the variables in the
model. Analyses were performed using STATA 10 SE (Stata Corp.,
College Station, TX).
Results
A total of 289 patients with sporadic NS were screened for
mutations ofNPHS1,NPHS2, and exons 8 and 9 ofWT1 starting
from 2001. Most patients underwent renal biopsy for clinical
reasons following our flowchart (see the Materials and Meth-
ods section). Overall, long-term clinical data were available for
seven and six carriers a single NPHS1 and NPHS2 mutations,
respectively. Data related to the outcome of NS in 27 patients
who carried NPHS2 variants (p.P20L and p.R229Q) were also
collected and reported in the following sections.
Heterozygous NPHS1 Mutations
NPHS1 mutations were heterozygous in seven and homozy-
gous in 11 cases (Table 1). All of these mutations produced
structural or functional problems in nephrin, were not observed
in normal control subjects (n  100) of comparable origin, and
had never been reported in a large database of NPHS1 variants
(1000 normals). Gender characteristics were distributed
equally between groups. Children with heterozygous NPHS1
received a diagnosis significantly later (mean age at onset 6.5
5.8 versus 0.9 2.7 yr; P 0.0054). As opposed to children with
homozygous mutations, all of whom were resistant to therapy,
five children with heterozygous mutations responded to ther-
apy. A pathology finding compatible with congenital nephrosis
of the Finnish type was present in all homozygous cases and in
none among heterozygous children.
After an average follow-up of 44 mo, nine children started
dialysis (incidence rate 0.010; range 0.005 to 0.019). These chil-
dren all were carriers of homozygous mutation (log-rank 2
4.58, P  0.0324).
Heterozygous NPHS2 Mutations and Variants
NPHS2mutations were heterozygous in six and homozygous
in 17 cases (Table 2). Twenty-seven patients carried a single
heterozygous variant (p.P20L in six cases, p.R229Q in 21 cases)
that predicted alteration of the encoded protein. Mutations and
p.P20L were not found in 300 Italian control subjects, whereas
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the p.R229Q allele frequency in the same population was 2%.
Moreover, the mutations described here have never been re-
ported in large databases and previous studies that overall
include 1000 individuals (3,25,26). Gender characteristics
were distributed equally between groups. Carriers of different
variants or single mutations (see Table 2) had similar age at
disease onset (mean 12.7  16.0 yr) with little variation among
groups. Overall, NS tended to be diagnosed later in children
with heterozygous NPHS2 than in children with homozygous
NPHS2 (4.7 6.0 yr; P 0.0157). Compared with children who
had homozygous mutations, who were resistant to drugs, the
response probability was 0.48 among heterozygous carriers.
The proportion of FSGS or IgM deposits tended to be lower in
the latter group (51 versus 71%; P  0.196).
After an average follow-up of 93 mo, 23 children started
dialysis (incidence rate 0.005; range 0.003 to 0.007). Children
who had heterozygous mutations with different NPHS2 vari-
ants had similar renal survival probabilities (log-rank 2 0.84,
P  0.656), which were significantly lower than those of chil-
dren with homozygous mutations (log-rank 2 5.27, P 
0.0217). Renal survival was significantly lower in the presence
of resistance to therapy (P  0.001) and FSGS or IgM deposits
(P  0.001) but was unaffected by gender or age categories.
Children with heterozygous variants experienced similar risk
for dialysis (Figure 1B) and also had the same risk as nonge-
netic cases of NS (Figure 1A). Cox regression showed that the
only significant predictor of dialysis was resistance to therapy
(hazard ratio 74.8; 95% confidence interval 10.2 to 548.0). When
this covariate was excluded from the model, heterozygous and
nongenetic forms were associated with similar risk for dialysis,
and only homozygous podocin mutation remained a significant
event predictor (hazard ratio 2.5; 95% confidence interval 1.4 to
4.5).
Discussion
In this article, we reviewed 40 cases of NS that were associ-
ated with a single mutation or a variant in NPHS1 or NPHS2. In
both cases, the number of patients enrolled (seven for NPHS1
and 33 for NPHS2) and the length of follow-up were adequate
to allow the definition of both clinical phenotypes and outcome.
The direct implication of a single mutation in a recessive con-
dition is behind the scope of our discussion because, as already
pointed out, it may underscore other, undetectable mutations
in noncoding regions of the same gene or in other interacting
genes. We cannot exclude that the presence of a heterozygous
mutation in one of the two major podocyte genes acts as a
modifier of the clinical phenotype. We considered, however,
that the clinical phenotype associated with heterozygous mu-
tations could reveal specific features of the disease and be of
importance for clinical purposes. Conversely, a good clinical
phenotype would indirectly support the concept that a single
mutation may be associated with NS with good prognosis. No
data of the literature are available on this aspect of NS, thereby
allowing no practical decision in terms of therapy and progno-
sis in these patients.
The main focus was therefore to review the clinical charac-
teristics of these patients with NS in relation to therapeutic
response and the outcome of renal function. A comparison was
done with a cohort of patients who had NS and were referred
to several Italian institutions and for whom a molecular
workup including sequence analysis of NPHS1, NPHS2, and
WT1 was available; therefore, these patients are not represen-
tative of the whole population of NS because they were fol-
lowed in a second-level nephrology center and underwent a
detailed molecular checkup. The results are for this reason
unique and offer a practical support for clinicians.
NPHS1
NPHS1 heterozygous mutations have been occasionally as-
sociated with NS in adults with minimal changes (only three
patients reported in the literature) (11,14). Several cases have
instead been described by Patrakka et al. (12), who reviewed
pregnancies that had been terminated because of raised con-
Figure 1. Kaplan-Meier survival analysis of time interval to
dialysis in different groups of patients with nephrotic syn-
drome. (A) Comparison of heterozygous carriers versus non-
NPHS1/NPHS2 and homozygous carriers of NPHS2 mutation.
(B) Three different groups of heterozygous carriers were split
according to the presence of p.P20L, p.R229Q, or other muta-
tions.
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centration of -protein and surprisingly found nine fetuses
heterozygous for Fin-major or Fin-minor with the other allele
devoid of any alteration. Renal pathology was reminiscent of
minimal lesions with effacement of foot processes and reduced
slit pores along the membrane; nephrin staining was main-
tained. Our cases, for which clinical details are available, are
therefore unique. The main clinical features were an early onset
of NS (between 1 and 16 yr), a histology of minimal lesions or
FSGS, and in most cases a good response to steroids and CsA.
Overall, these clinical features underlie a good outcome, and
even though the follow-up is limited, the response to drugs
suggests nonprogression to renal failure (27).
NPHS2
In the literature, the description of an association of heterozy-
gous mutations in NPHS2 with NS is confined to cohorts of
patients with limited follow-up (for review, see reference [13]).
Recently, Hinkes et al. (9) reported an incidence of 2.0 and 5.5%,
respectively, of single (unspecified)NPH2mutations and p.R229Q
variant in a large European cohort of pediatric patients with NS
(Arbeitsgemeinschaft fu¨r Pa¨diatrische Nephrologie Study Group).
More recently, Tonna et al. (16) screened amixed population of 371
children and adults with NS (median age at onset 25 yr) and
found 51 patients with a single heterozygous allele that predicted
an altered protein. Most of these patients carried p.R229Q (n 32)
and a few p.R138Q (n  3). Both studies limited the clinical
observation to the age of onset of NS and found no difference
compared with patients with two missense mutations and/or
with classical NS. Our study confirms and further extends the
description of clinical features in three cohorts of patients that
included six patients who carried a heterozygous mutation with
changes in the amino acid sequence or a frameshift, six patients
who carried p.P20L, and 21 patients with heterozygous p.R229Q.
On this basis, our study is the first to report clinical details (renal
pathology, response to drugs, and evolution to end-stage renal
failure) in a population that represents a significant part of all NS
(2.2% considering only heterozygous mutations, 9.9% considering
p.P20L and p.R229Q).
p.P20L is a variant of unclear functional significance that is not
considered a mutation. Actually, in vitro experiments showed that
the presence of p.P20L tended to reduce plasma membrane podo-
cin localization (28). Data on the presence of p.P20L in normal
cohorts are conflicting.We and others could not find p.P20L in 400
European control subjects (6,13,25), and the same was found in an
unpublished database from the National Institutes of Health in
634 black individuals reported by Franceschini et al. (26). The null
incidence of P20L was changed in an article from the same au-
thors, which reported 1.3% of 621 black individuals with p.P20L
(15). Ruf et al. (5) reported the presence of two homozygous
p.P20L carriers out of 80 normal control subjects, an incidence that
is out of the Hardy-Weinberg equilibrium as a result of absence of
heterozygous carriers in the same cohort (theoretical incidence 16
patients instead of one). p.P20L is a part of a haplotype with a
variant in the NPHS2 promoter (rs59301652) that is associated
with marked downregulation of podocin expression (25). This
haplotype that includes p.P20L and rs1079292 was found only in
patients with renal disease, mostly in patients with nephrosis and
less frequently in patients with IgA nephropathy (P  0.035).
The p.R229Q variant is a common polymorphism that occurs
at an increased frequency in association with late-onset FSGS.
Pulldown experiments with antipodocin antibodies demon-
strated a decreased binding to nephrin in the presence of this
polymorphism (29). It was proposed that this common variant
may predispose to microalbuminuria (30) or contribute to glo-
merulosclerosis in association with another mutant NPHS2 al-
lele or acting in synergism with other factors. In our series of
271 patients with NS, p.R229Q had an allele frequency (3.8%)
that is very close to the incidence reported by Hinkes et al. (9)
in the Arbeitsgemeinschaft fu¨r Pa¨diatrische Nephrologie pop-
ulation (3.2%), whereas in our normal control subjects it was
2%. McKenzie et al. (15) reported a low allele frequency (1.3 and
1.0%) in 634 normal individuals and 247 black patients with NS,
whereas they did find a notable 3.9 and 4.7% in 271 normal
individuals and 129 white patients with NS. This variability
makes it difficult to discern the association between p.R229Q
and NS. Our results showing comparable clinical features in
patients who carry the two variants reduce the problem to a
mere pathophysiology aspect and conclusively show that they
do not predispose to particular clinical features. In fact, the age
of onset of NS was comparable between carriers of different
variants (p.P20L and p.R229Q) and those with NPHS2 muta-
tions. In general, steroid resistance was frequent (60 to 70%),
and, with the exception of three cases, CsA reduced proteinuria
when it was used. One single patient failed to respond to CsA
but had a lasting remission with tacrolimus and steroids. Pro-
gression to end-stage renal failure occurred in 30 to 40% of
cases and was comparable with other NS.
Conclusions
The main conclusion is that children who have heterozygous
mutations with different variants have similar renal survival
probabilities that are significantly better than those of children
with homozygous mutations. They must be treated with the
same therapeutic approaches used for patients without
NPHS1/NPHS2 mutations and have good chances for a posi-
tive outcome. Resistance to therapy is a main characteristics
that predicts a bad outcome. Overall, these patients should be
treated following consolidated schemes with good chances for
a long-term outcome similar to the other patients who do not
carry NPHS1 or NPHS2 mutations.
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